Contact:
Dr. Misha Plam
President and CEO
T: (303) 641-3669
misha.plam@amidebio.com
www.amidebio.com

AmideBio CTO Dr. Michael Stowell's structural work on a potential novel target for Alzheimer's published in Nature Scientific Reports

BOULDER, CO, October 17, 2015 – AmideBio, LLC, a privately held biopharmaceutical company, announced that AmideBio's CTO, Dr. Michael H. B. Stowell recently published an article in Nature Scientific Reports entitled "Architecture of the Synaptophysin/Synaptobrevin Complex: Structural Evidence for an Entropic Clustering Function at the Synapse" (http://www.nature.com/articles/srep13659).

Dr. Stowell's ongoing research activities at the University of Colorado has been devoted to finding novel molecular targets in Alzheimer's disease and this paper describes the first structural information for the Synaptophysin/Synaptobrevin complex. Dr. Stowell and University of Colorado graduate students Daniel J. Adams and Christopher P. Arthur used a combination of single particle electron microscopy and molecular modelling to elucidate the architecture of this highly abundant complex at the synapse. Ongoing research carried out in Dr. Stowell's lab has identified the Synaptophysin/Synaptobrevin as a potential target in Alzheimer's.

"The publication of this article is an important step in the quest for understanding the cause of Alzheimer's disease" said Dr. Misha Plam, AmideBio's President and CEO. "Dr. Stowell's main research at the University of Colorado, has been devoted to understanding the causes of Alzheimer's disease. His research has been hampered by the lack of ultrapure amyloid peptides and AmideBio, LLC was started in 2010 in order to develop commercial quantities of ultrapure amyloid for his research and for other scientists who are devoted to developing a cure for Alzheimer's. We are very happy to see the results of his research efforts published."

About AmideBio:
AmideBio, based in Boulder, CO, is a biotechnology company leveraging its proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides to researchers and the industry, while also building a pipeline of novel biotherapeutics. AmideBio's proprietary technology enables the rapid and economical manufacture of pure peptides of any length. This innovative technology combines recombinant and chemical methods, eliminates many of the inefficient and costly steps of processes that rely only on one or the other approach and, results in fewer batch inconsistencies and less waste generation. These advantages enable AmideBio to offer its cost-efficient technology and peptide product candidates to the pharmaceutical and biotech industry. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.

- ENDS -